Sainte Consorce, France

Warren Viricel

This inventor holds 2 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignees: Mablink Bioscience, Centre National De La Recherche Scientifique, Eli Lilly and Company. Active years: 2025-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Warren Viricel. Retrieved from https://idiyas.com/inventor/warren-viricel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 50.0

 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2025-2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Warren Viricel: Innovator in Antibody Drug Conjugates

Introduction

Warren Viricel is a notable inventor based in Sainte Consorce, France. He has made significant contributions to the field of cancer treatment through his innovative work on antibody drug conjugates (ADCs). His research focuses on developing targeted therapies that can improve patient outcomes.

Latest Patents

Warren Viricel holds 1 patent for an antibody drug conjugate targeting Nectin 4, which comprises an exatecan payload. This patent outlines the use of Nectin-4 ADCs in pharmaceutical compositions and methods for treating cancer. His work represents a promising advancement in targeted cancer therapies.

Career Highlights

Throughout his career, Warren has worked with prominent organizations, including Eli Lilly and Company and Université D'Aix-Marseille. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Warren has collaborated with notable colleagues such as Jacobus Petrus Maria Elands and Joanna Fares. These partnerships have further enriched his research and development efforts in the area of antibody drug conjugates.

Conclusion

Warren Viricel's innovative work in the field of antibody drug conjugates highlights his commitment to advancing cancer treatment. His contributions are paving the way for more effective therapies that can significantly impact patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…